Dr. G. David Young, DVM, DACVP, DABT
Dr. Young has 25-plus years of broad and varied experience in biomedical research in the US Government, toxicology testing laboratories and the pharmaceutical industry. His experience includes oncology and biomarker research and development, digital pathology, image analysis, veterinary pathology, toxicological pathology, and toxicity testing. Management experience includes being the founding Director of the Directorate of Toxicology at the US Army Center for Health Promotion and Preventive Medicine; Director of Toxicology at Spring Valley Laboratory; Senior Vice President, Lab Services Division, TherImmune Research Corporation and Director of Pathology, OSI Pharmaceuticals, Inc. He is board certified by the American College of Veterinary Pathologists and the American Board of Toxicology.
Dr. Frank Voelker, DVM, DACVP, MS
Dr. Voelker has 35-plus years of experience in US Government, pharmaceutical industry and contract research laboratories. His experience includes areas involving experimental and discovery pathology, toxicologic pathology and toxicity testing, oncology and biomarker research, ultrastructural pathology, peer review pathology, digital pathology, image analysis and immunohistochemistry. His management background includes Chief, Division of Anatomic and Comparative Pathology, Naval Medical Research Institute, Director and founder of Electron Microscopy Laboratory, Burroughs Welcome Co., Operations Director and founder of North Carolina Pathology Laboratory, Pathology Associates Inc., Director of Pathology, TSI Mason Laboratories, Tissue Biomarker Laboratory Head, and founder, Localization Confirmation, and later Section Head, Marker Localization and Assays at Novartis Institutes for Biomedical Research. He is board certified by the American College of Veterinary Pathologists.
Dr. David Eberhard, M.D., Ph.D., Chief Medical Pathologist
Dr. Eberhard is an anatomic/molecular pathologist widely recognized for his leadership in oncology clinical trials. He was previously the Director of Clinical Trials Pathology Services at LabCorp’s Center for Molecular Biology and Pathology, where he joined after a distinguished career at Genentech and as an industry consultant. He is an Associate Professor at University of North Carolina, Chapel Hill, and has been active in developing standardized approaches for molecular pathologic analyses of solid tumors in clinical trials. Dr. Eberhard has been active in developing standardized approaches for molecular pathologic analyses of solid tumors in clinical trials, such as the publication of industry working group recommendations for EGFR testing in pathology.
Holger Lange, Ph.D., Chief Techology Officer
Joseph Krueger, Ph.D. Director of Biology
Dr. Krueger is an established cancer researcher and industry veteran, who received his Ph.D. in Cancer Biology from Wayne State University, and performed his postdoctoral research at The University of California San Diego, and The Scripps Research Institute. As a cancer researcher, Joseph was repeatedly funded and published, and continues to author collaborative publications pertaining to breast cancer progression and metastases. After his postdoctoral training, Joseph worked as a Senior Scientist at OSI Pharmaceuticals, where he joined David Young in a pivotal role to identify EMT biomarkers for their translation into clinical diagnostics. Immediately prior to joining Flagship, Joseph also served as a Principle Scientist at Pfizer in the Oligonucleotide Therapeutics Unit. Prior to his appointment as Director of Biology at Flagship, Joseph also led Flagship’s Scientific Advisory Board.
Robert S. Kellar, Ph.D.
Dr. Kellar is Founder and President of Development Engineering Sciences, LLC, a biomedical consulting firm. He has 14 years of experience in the development and regulatory approval of medical devices, cell-based products, and tissue engineered technology. Previously, Dr. Kellar was VP for Research and Development at Histogen, Inc. where he led multi-functional project teams for all aspects of product development. Prior to Histogen, Dr. Kellar was a product specialist for the first FDA-approved thoracic endograft at W.L. Gore and Associates where he served a lead role in development, regulatory, clinical trials, marketing, sales, and business for the thoracic device and the product portfolio. Previous to this position, Dr. Kellar was a product specialist for the Global Oral Health Business at W.L. Gore & Associates (both Gore-Tex® Regenerative Membranes and the entire resorbable membrane portfolio). Prior to Gore, at Advanced Tissue Sciences, Inc. he led cardiovascular research programs and managed the AngineraTM program. Dr. Kellar serves on the Scientific Advisory Board for Theregen, and holds an Adjunct Professor Faculty position in Mechanical Engineering. He serves as an advisory Board Member for Protein Genomics, a regenerative medicine company. Dr. Kellar also serves on the Board of Directors for the Surfaces in Biomaterials Foundation.
Trevor D. Johnson, M.S., Director of Tissue Analysis Services
Trevor Johnson is an expert in the use of image analysis for pharmaceutical and medial device applications. He has developed quantitative algorithms and high throughput workflow solutions for tissue analysis in several disease areas using multiple imaging modalities. Trevor has conducted training, image analysis seminars, and developed custom solutions for many large pharmaceutical and medical device companies. He has a M.S. in Engineering from UCLA and has experience working in image analysis for cancer applications with several medical device companies including Aperio and QinetiQ North America.
